CCL5 secreted by senescent aged fibroblasts induces proliferation of prostate epithelial cells and expression of genes that modulate angiogenesis

Journal of Cellular Physiology

Volumn 220, Issue 2, 2009, Pages 376-381

  Eyman, D ^a   Damodarasamy, M ^a   Plymate, S R ^b   Reed, M J ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES;

ANGIOGENESIS; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CELL STIMULATION; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIUM CELL; FIBROBLAST; GENE EXPRESSION; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROSTATE EPITHELIUM; PROSTATE HYPERTROPHY; PROTEIN FUNCTION; PROTEIN MICROARRAY; SENESCENCE; TISSUE GROWTH; AGE; AGED; CELL AGING; CELL LINE; CELL MOTION; CHEMISTRY; CULTURE MEDIUM; CYTOLOGY; DNA MICROARRAY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROSTATE;

AGE FACTORS; AGED, 80 AND OVER; CELL AGING; CELL LINE; CELL MOVEMENT; CELL PROLIFERATION; CHEMOKINE CCL5; CULTURE MEDIA, CONDITIONED; EPITHELIAL CELLS; FIBROBLASTS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; MALE; NEOVASCULARIZATION, PHYSIOLOGIC; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROSTATE; PROSTATIC HYPERPLASIA;

EID: 67649382172     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.21776     Document Type: Article

References (55)

1. Adler EP, Lemken CA, Katchen NS, Kurt RA. 2003. Adual role for tumor-derived chemokine RANTES (CCL5). Immunol Lett 90:187-194.
2. Aldinucci D, Lorenzon D, Cattaruzza L, Pinto A,Gloghini A,Carbone A, Colombatti A. 2008. Expression of CCR5 receptors on Reed-Sternberg cells and Hodgkin lymphoma cell lines: Involvement of CCL5/Rantes in tumor cell growth and microenvironmental interactions. Int J Cancer 122:769-776.
3. Ao M, Franco OE, Park D, Raman D, Williams K, Hayward SW. 2007. Cross-talk between paracrine-acting cytokine and chemokine pathways promotes malignancy in benign human prostatic epithelium. Cancer Res 67:4244-4253.
4. Azenshtein E, Luboshits G, Shina S, Neumark E, Shahbazian D, Weil M,Wigler N, Keydar I, Ben-Baruch A. 2002. The CC chemokine RANTES in breast carcinoma progression: Regulation of expression and potential mechanisms of promalignant activity. Cancer Res 62:1093-1102.
5. Bakhiet M, Tjernlund A, Mousa A, Gad A, Stromblad S, Kuziel WA, Seiger A, Andersson J. 2001. RANTES promotes growth and survival of human first-trimester forebrain astrocytes. Nat Cell Biol 3:150-157.
6. Balducci L, Ershler WB. 2005. Cancer and ageing: A nexus at several levels. Nat Rev Cancer 5:655-662.
7. Bavik C, Coleman I, Dean JP, Knudsen B, Plymate S, Nelson PS. 2006. The gene expression program of prostate fibroblast senescence modulates neoplastic epithelial cell proliferation through paracrine mechanisms. Cancer Res 66:794-802.
8. Begley L, Monteleon C, Shah RB, Macdonald JW,Macoska JA. 2005. CXCL12 overexpression and secretion by aging fibroblasts enhance human prostate epithelial proliferation in vitro. Aging Cell 4:291-298.
9. Begley LA, MacDonald JW, Day ML, Macoska JA. 2007. CXCL12 activates a robust transcriptional response in human prostate epithelial cells. J Biol Chem 282:26767-26774.
10. Begley LA, Kasina S, MacDonald J, Macoska JA. 2008. The inflammatory microenvironment of the aging prostate facilitates cellular proliferation and hypertrophy. Cytokine 43:194-199.
11. Belloni D, Scabini S, Foglieni C, Veschini L, Giazzon A, Colombo B, Fulgenzi A, Helle KB, Ferrero ME, Corti A, Ferrero E. 2007. The vasostatin-I fragment of chromogranin A inhibits VEGF-induced endothelial cell proliferation and migration. FASEB J 21:3052-3062.
12. Borczuk AC, Papanikolaou N, Toonkel RL, Sole M, Gorenstein LA, Ginsburg ME, Sonett JR, Friedman RA, Powell CA. 2008. Lung adenocarcinoma invasion in TGFbetaRII-deficient cells is mediated by CCL5/RANTES. Oncogene 27:557-564.
13. Campisi J. 2005. Senescent cells, tumor suppression, and organismal aging: Good citizens, bad neighbors. Cell 120:513-522.
14. Capoulade-Metay C, Ayouba A, Kfutwah A, Lole K, Petres S, Dudoit Y, Deterre P, Menu E, Barre-Sinoussi F, Debre P, Theodorou I. 2006.Anatural CCL5/RANTES variant antagonist for CCR1 and CCR3. Immunogenetics 58:533-541.
15. Castro P, Giri D, Lamb D, Ittmann M. 2003. Cellular senescence in the pathogenesis of benign prostatic hyperplasia. Prostate 55:30-38.
16. Castro P, Xia C, Gomez L, Lamb DJ, Ittmann M. 2004. Interleukin-8 expression is increased in senescent prostatic epithelial cells and promotes the development of benign prostatic hyperplasia. Prostate 60:153-159.
17. Choi J, Shendrik I, Peacocke M, Peehl D, Buttyan R, Ikeguchi EF, Katz AE, Benson MC. 2000. Expression of senescence-associated beta-galactosidase in enlarged prostates from men with benign prostatic hyperplasia. Urology 56:160-166.
18. Corti S, Salani S, Del Bo R, Sironi M, Strazzer S, D'Angelo MG, Comi GP, Bresolin N, Scarlato G. 2001. Chemotactic factors enhance myogenic cell migration across an endothelial monolayer. Exp Cell Res 268:36-44.
19. Crola Da Silva C, Lamerant-Fayel N, Paprocka M, Mitterrand M, Gosset D, Dus D, Kieda C. 2009. Selective human endothelial cell activation by chemokines as a guide to cell homing. Immunology 126:394-404.
20. Dean JP, Nelson PS. 2008. Profiling influences of senescent and aged fibroblasts on prostate carcinogenesis. Br J Cancer 98:245-249.
21. Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C, Medrano EE, Linskens M, Rubelj I, Pereira-Smith O, Peacocke M, Campisi J. 1995. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci USA 92:9363-9367.
22. DiPaolo BR, Pignolo RJ, Cristofalo VJ. 1995. Identification of proteins differentially expressed in quiescent and proliferatively senescent fibroblast cultures. Exp Cell Res 220:178-185.
23. Doll JA, Reiher FK, Crawford SE, Pins MR, Campbell SC, Bouck NP. 2001. Thrombospondin-1, vascular endothelial growth factor and fibroblast growth factor-2 are key functional regulators of angiogenesis in the prostate. Prostate 49:293-305.
24. Egeblad M, Littlepage LE, Werb Z. 2005. The fibroblastic coconspirator in cancer progression. Cold Spring Harb Symp Quant Biol 70:383-388.
25. Elsner J, Mack M, Bruhl H, Dulkys Y, Kimmig D, Simmons G, Clapham PR, Schlondorff D, Kapp A, Wells TN, Proudfoot AE. 2000. Differential activation of CC chemokine receptors by AOP-RANTES. J Biol Chem 275:7787-7794.
26. Gaston SM, Soares MA, Siddiqui MM, Vu D, Lee JM, Goldner DL, Brice MJ, Shih JC, Upton MP, Perides G, Baptista J, Lavin PT, Bloch BN, Genega EM, Rubin MA, Lenkinski RE. 2005. Tissue-print and print-phoresis as platform technologies for the molecular analysis of human surgical specimens: Mapping tumor invasion of the prostate capsule. Nat Med 11:95-101.
27. Giri D, Ittmann M. 2000. Interleukin-1alpha is a paracrine inducer of FGF7, a key epithelial growth factor in benign prostatic hyperplasia. Am J Pathol 157:249-255.
28. Giri D, Ittmann M. 2001. Interleukin-8 is a paracrine inducer of fibroblast growth factor 2, a stromal and epithelial growth factor in benign prostatic hyperplasia. Am J Pathol 159:139-147.
29. Hamano Y, Kalluri R. 2005. Tumstatin, the NC1 domain of alpha3 chain of type IV collagen, is an endogenous inhibitor of pathological angiogenesis and suppresses tumor growth. Biochem Biophys Res Commun 333:292-298.
30. Hayward SW, Dahiya R, Cunha GR, Bartek J, Deshpande N, Narayan P. 1995. Establishment and characterization of an immortalized but non-transformed human prostate epithelial cell line: BPH-1. In Vitro Cell Dev Biol Anim 31:14-24.
31. Katona TM, Neubauer BL, Iversen PW, Zhang S, Baldridge LA, Cheng L. 2005. Elevated expression of angiogenin in prostate cancer and its precursors. Clin Cancer Res 11:8358-8363.
32. Konig JE, Senge T, Allhoff EP, Konig W. 2004. Analysis of the inflammatory network in benign prostate hyperplasia and prostate cancer. Prostate 58:121-129.
33. Liu D, Hornsby PJ. 2007. Senescent human fibroblasts increase the early growth of xenograft tumors via matrix metalloproteinase secretion. Cancer Res 67:3117-3126.
34. Magnusson PU, Dimberg A, Mellberg S, Lukinius A, Claesson-Welsh L. 2007. FGFR-1 regulates angiogenesis through cytokines interleukin-4 and pleiotrophin. Blood 110:4214-4222.
35. Mishra VC, Allen DJ, Nicolaou C, Sharif H, Hudd C, Karim OM, Motiwala HG, Laniado ME. 2007. Does intraprostatic inflammation have a role in the pathogenesis and progression of benign prostatic hyperplasia? BJU Int 100:327-331.
36. Nelen V. 2007. Epidemiology of prostate cancer. Recent Results Cancer Res 175:1-8.
37. Nickel JC. 2008. Inflammation and benign prostatic hyperplasia. Urol Clin North Am 35:109-115 vii.
38. Nyberg P, Xie L, Kalluri R. 2005. Endogenous inhibitors of angiogenesis. Cancer Res 65:3967-3979.
39. Perez-Pinera P, Chang Y, Deuel TF. 2007. Pleiotrophin, a multifunctional tumor promoter through induction of tumor angiogenesis, remodeling of the tumor microenvironment, and activation of stromal fibroblasts. Cell Cycle 6:2877-2883.
40. Perez-Pinera P, Berenson JR, Deuel TF. 2008. Pleiotrophin, a multifunctional angiogenic factor: Mechanisms and pathways in normal and pathological angiogenesis. Curr Opin Hematol 15:210-214.
41. Reed MJ, Vernon RB, Abrass IB, Sage EH. 1994. TGF-beta 1 induces the expression of type I collagen and SPARC, and enhances contraction of collagen gels, by fibroblasts from young and aged donors. J Cell Physiol 158:169-179.
42. Reed MJ, Ferara NS, Vernon RB. 2001. Impaired migration, integrin function, and actin cytoskeletal organization in dermal fibroblasts from a subset of aged human donors. Mech Ageing Dev 122:1203-1220.
43. Ren B, Yu YP, Tseng GC, Wu C, Chen K, Rao UN, Nelson J, Michalopoulos GK, Luo JH. 2007. Analysis of integrin alpha7 mutations in prostate cancer, liver cancer, glioblastoma multiforme, and leiomyosarcoma. J Natl Cancer Inst 99:868-880.
44. Rumpold H, Mascher K, Untergasser G, Plas E, Hermann M, Berger P. 2002. Transdifferentiation of prostatic stromal cells leads to decreased glycoprotein hormone alpha production. J Clin Endocrinol Metab 87:5297-5303.
45. Sadoun E, Reed MJ. 2003. Impaired angiogenesis in aging is associated with alterations in vessel density, matrix composition, inflammatory response, and growth factor expression. J Histochem Cytochem 51:1119-1130.
46. Singh S, Sadanandam A, Singh RK. 2007. Chemokines in tumor angiogenesis and metastasis. Cancer Metastasis Rev 26:453-467.
47. Sprenger CC, Plymate SR, Reed MJ. 2008. Extracellular influences on tumour angiogenesis in the aged host. Br J Cancer 98:250-255.
48. Stormes KA, Lemken CA, Lepre JV, Marinucci MN, Kurt RA. 2005. Inhibition of metastasis by inhibition of tumor-derived CCL5. Breast Cancer Res Treat 89:209-212.
49. Swift ME, Kleinman HK, DiPietro LA. 1999. Impaired wound repair and delayed angiogenesis in aged mice. Lab Invest 79:1479-1487.
50. True LD, Hawley S, Norwood TH, Braun KR, Evanko SP, Chan CK, Lebaron RC, Wight TN. 2009. The accumulation of versican in the nodules of benign prostatic hyperplasia. Prostate 69:149-158.
51. Untergasser G, Madersbacher S, Berger P. 2005. Benign prostatic hyperplasia: Age-related tissue-remodeling. Exp Gerontol 40:121-128.
52. Vacherot F, Caruelle D, Chopin D, Gil-Diez S, Barritault D, Caruelle JP, Courty J. 1999. Involvement of heparin affin regulatory peptide in human prostate cancer. Prostate 38:126-136.
53. Vaday GG, Peehl DM, Kadam PA, Lawrence DM. 2006. Expression of CCL5 (RANTES) and CCR5 in prostate cancer. Prostate 66:124-134.
54. Westerweel PE, Rabelink TJ, Rookmaaker MB, Grone HJ, Verhaar MC. 2008. RANTES is required for ischaemia-induced angiogenesis, which may hamper RANTES-targeted antiatherosclerotic therapy. Thromb Haemost 99:794-795.
55. Yoshioka N,Wang L, Kishimoto K, Tsuji T, Hu GF. 2006. A therapeutic target for prostate cancer based on angiogenin-stimulated angiogenesis and cancer cell proliferation. Proc Natl Acad Sci USA 103:14519-14524.